Pulmonx downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Jason Bednar downgraded Pulmonx (LUNG) to Neutral from Overweight with a price target of $2.50, down from $9, following the Q2 report. The company posted its sixth consecutive quarter of decollation in the high-margin U.S. business. Piper no longer has confidence in management’s updated full-year outlook or that Pulmonx can return to 15%-20% sales growth.